Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

First Alzheimer's Blood Test for Adults with Cognitive Symptoms as Young as 40

21 August 2026 · By · Wire by Fusion42

Published

21 August 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at ncnewsonline.com →

◆ Verified

Fusion42 · 21 August 2026 · Fusion42 review

The FDA has cleared C2N Diagnostics' PrecivityAD2®, the first blood test for Alzheimer’s diagnosis in adults aged 40 and older with cognitive symptoms, providing a scalable and less invasive option than PET or cerebrospinal fluid testing.

This Wire brief sits within Fusion42's coverage of Medtech, and 4 sources have reported it between 20 Aug 2026 and 21 Aug 2026.

◆ ◆ The Wire takeaway

You can now target earlier-stage Alzheimer’s diagnosis without expensive scans. If your Medtech startup works on brain health or diagnostics, this clearance opens a new route for clinical adoption and reimbursement.

◆ Coverage

4 sources · first reported 20 Aug 2026 · latest 21 Aug 2026

◆ Related on Wire

◆ Topics

Medtechalzheimersblood-testFDA-clearancecognitive-impairmentdiagnostics